The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
The results of the phase 1/2 LIBRETTO-001 clinical trial has recently established the efficacy of the RET inhibitor selpercatinib in RET-driven cancers. Here, the authors characterize the molecular determinants of response and resistance in 72 LIBRETTO-001 lung and thyroid cancer patients treated at...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-03-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-022-28848-x |
| _version_ | 1818774201266339840 |
|---|---|
| author | Ezra Y. Rosen Helen H. Won Youyun Zheng Emiliano Cocco Duygu Selcuklu Yixiao Gong Noah D. Friedman Ino de Bruijn Onur Sumer Craig M. Bielski Casey Savin Caitlin Bourque Christina Falcon Nikeysha Clarke Xiaohong Jing Fanli Meng Catherine Zimel Sophie Shifman Srusthi Kittane Fan Wu Marc Ladanyi Kevin Ebata Jennifer Kherani Barbara J. Brandhuber James Fagin Eric J. Sherman Natasha Rekhtman Michael F. Berger Maurizio Scaltriti David M. Hyman Barry S. Taylor Alexander Drilon |
| author_facet | Ezra Y. Rosen Helen H. Won Youyun Zheng Emiliano Cocco Duygu Selcuklu Yixiao Gong Noah D. Friedman Ino de Bruijn Onur Sumer Craig M. Bielski Casey Savin Caitlin Bourque Christina Falcon Nikeysha Clarke Xiaohong Jing Fanli Meng Catherine Zimel Sophie Shifman Srusthi Kittane Fan Wu Marc Ladanyi Kevin Ebata Jennifer Kherani Barbara J. Brandhuber James Fagin Eric J. Sherman Natasha Rekhtman Michael F. Berger Maurizio Scaltriti David M. Hyman Barry S. Taylor Alexander Drilon |
| author_sort | Ezra Y. Rosen |
| collection | DOAJ |
| description | The results of the phase 1/2 LIBRETTO-001 clinical trial has recently established the efficacy of the RET inhibitor selpercatinib in RET-driven cancers. Here, the authors characterize the molecular determinants of response and resistance in 72 LIBRETTO-001 lung and thyroid cancer patients treated at a single site. |
| first_indexed | 2024-12-18T10:37:23Z |
| format | Article |
| id | doaj.art-c9aadc1f6bbc44acba731c2a7dcb7aef |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-12-18T10:37:23Z |
| publishDate | 2022-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-c9aadc1f6bbc44acba731c2a7dcb7aef2022-12-21T21:10:43ZengNature PortfolioNature Communications2041-17232022-03-011311910.1038/s41467-022-28848-xThe evolution of RET inhibitor resistance in RET-driven lung and thyroid cancersEzra Y. Rosen0Helen H. Won1Youyun Zheng2Emiliano Cocco3Duygu Selcuklu4Yixiao Gong5Noah D. Friedman6Ino de Bruijn7Onur Sumer8Craig M. Bielski9Casey Savin10Caitlin Bourque11Christina Falcon12Nikeysha Clarke13Xiaohong Jing14Fanli Meng15Catherine Zimel16Sophie Shifman17Srusthi Kittane18Fan Wu19Marc Ladanyi20Kevin Ebata21Jennifer Kherani22Barbara J. Brandhuber23James Fagin24Eric J. Sherman25Natasha Rekhtman26Michael F. Berger27Maurizio Scaltriti28David M. Hyman29Barry S. Taylor30Alexander Drilon31Department of Medicine, Memorial Sloan Kettering Cancer CenterMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterDepartment of Pathology, Memorial Sloan Kettering Cancer CenterDepartment of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterDepartment of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterDepartment of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterDepartment of Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Medicine, Memorial Sloan Kettering Cancer CenterMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterDepartment of Pathology, Memorial Sloan Kettering Cancer CenterDepartment of Pathology, Memorial Sloan Kettering Cancer CenterDepartment of Pathology, Memorial Sloan Kettering Cancer CenterDepartment of Pathology, Memorial Sloan Kettering Cancer CenterLoxo Oncology at LillyLoxo Oncology at LillyLoxo Oncology at LillyDepartment of Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Pathology, Memorial Sloan Kettering Cancer CenterMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterDepartment of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterLoxo Oncology at LillyMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterDepartment of Medicine, Memorial Sloan Kettering Cancer CenterThe results of the phase 1/2 LIBRETTO-001 clinical trial has recently established the efficacy of the RET inhibitor selpercatinib in RET-driven cancers. Here, the authors characterize the molecular determinants of response and resistance in 72 LIBRETTO-001 lung and thyroid cancer patients treated at a single site.https://doi.org/10.1038/s41467-022-28848-x |
| spellingShingle | Ezra Y. Rosen Helen H. Won Youyun Zheng Emiliano Cocco Duygu Selcuklu Yixiao Gong Noah D. Friedman Ino de Bruijn Onur Sumer Craig M. Bielski Casey Savin Caitlin Bourque Christina Falcon Nikeysha Clarke Xiaohong Jing Fanli Meng Catherine Zimel Sophie Shifman Srusthi Kittane Fan Wu Marc Ladanyi Kevin Ebata Jennifer Kherani Barbara J. Brandhuber James Fagin Eric J. Sherman Natasha Rekhtman Michael F. Berger Maurizio Scaltriti David M. Hyman Barry S. Taylor Alexander Drilon The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers Nature Communications |
| title | The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers |
| title_full | The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers |
| title_fullStr | The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers |
| title_full_unstemmed | The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers |
| title_short | The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers |
| title_sort | evolution of ret inhibitor resistance in ret driven lung and thyroid cancers |
| url | https://doi.org/10.1038/s41467-022-28848-x |
| work_keys_str_mv | AT ezrayrosen theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT helenhwon theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT youyunzheng theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT emilianococco theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT duyguselcuklu theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT yixiaogong theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT noahdfriedman theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT inodebruijn theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT onursumer theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT craigmbielski theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT caseysavin theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT caitlinbourque theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT christinafalcon theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT nikeyshaclarke theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT xiaohongjing theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT fanlimeng theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT catherinezimel theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT sophieshifman theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT srusthikittane theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT fanwu theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT marcladanyi theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT kevinebata theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT jenniferkherani theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT barbarajbrandhuber theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT jamesfagin theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT ericjsherman theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT natasharekhtman theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT michaelfberger theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT maurizioscaltriti theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT davidmhyman theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT barrystaylor theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT alexanderdrilon theevolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT ezrayrosen evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT helenhwon evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT youyunzheng evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT emilianococco evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT duyguselcuklu evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT yixiaogong evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT noahdfriedman evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT inodebruijn evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT onursumer evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT craigmbielski evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT caseysavin evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT caitlinbourque evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT christinafalcon evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT nikeyshaclarke evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT xiaohongjing evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT fanlimeng evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT catherinezimel evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT sophieshifman evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT srusthikittane evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT fanwu evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT marcladanyi evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT kevinebata evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT jenniferkherani evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT barbarajbrandhuber evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT jamesfagin evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT ericjsherman evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT natasharekhtman evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT michaelfberger evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT maurizioscaltriti evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT davidmhyman evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT barrystaylor evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers AT alexanderdrilon evolutionofretinhibitorresistanceinretdrivenlungandthyroidcancers |